Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on July 28, 2025
Xtant Medical Partners with B2i Digital to Educate Investors on Its Orthobiologics Innovation and Market Opportunity
Partnership will deliver centralized investor-focused content for investors to gain insight into Xtant’s orthobiologics platform and long-term value proposition Xtant Medical Holdings, Inc. (NYSE:XTNT) NEW YORK, NY, UNITED STATES, July 28, 2025 / …
Aspen HR Honored as a 'Best Place for Working Parents' for Fourth Consecutive Year
Aspen HR proudly announces it has been named one of the Best Places for Working Parents for the fourth consecutive year. NEW YORK CITY, NY, UNITED STATES, July 28, 2025 /EINPresswire.com/ -- Aspen HR, a leading white-glove Certified Professional …
RouteGenie Launches Automated Text-Based Tracking Links to Enhance Rider Communication
RouteGenie launches automated text-based trip tracking links, allowing passengers to follow rides in real time via SMS. Setup fees are waived through July 31. BUFFALO, NY, UNITED STATES, July 28, 2025 /EINPresswire.com/ -- RouteGenie, the leading Non- …
SCHEQ Foundation Launches Inaugural Patient Advisory Board to Advance Health Literacy and Equity in Cancer Care
Diverse Patient Voices Will Guide Development of Culturally Relevant Resources and Improve Accessibility of Cancer Information NEW YORK, NY, UNITED STATES, July 28, 2025 /EINPresswire.com/ -- The STEMM …
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant …
North Park Nursing Student Receives Prestigious Schweitzer Fellowship
Chicago, July 28, 2025 (GLOBE NEWSWIRE) -- Victoria Roehl, a student in the Master of Nursing Leadership program at North Park University (NPU), has been named a 2025–26 Schweitzer Fellow, a prestigious honor given to graduate students to lead innovative, …
Strength Building: How Strength Training Supplements Help You Build Muscle Mass and Keep Growing Stronger - CrazyBulk
New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025 In the evolving world of performance fitness, …
Regional Health Properties, Inc. Outlines Reasons for Regional Shareholders to Vote YES for Proposed Merger with SunLink Health Systems, Inc.
ATLANTA, GA, July 28, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior …
Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status
CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) received two different communications from the staff of the Nasdaq Listing Qualifications office of the Nasdaq Stock Market, LLC. The Company …
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025
SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2025 financial and …
Correction: iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering
WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects a version issued on July 25, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not currently affiliated with iSpecimen …
Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results
Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4 Consolidated Adjusted EBITDA is the 2nd Highest in the Company’s History International Cannabis Revenue Increased 71% in Q4 …
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated Information Châtillon, France, July 28, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical …
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
Informations Réglementées Châtillon, France, le 28 juillet (22 h 30 CET) 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), laboratoire biopharmaceutique …
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced …
Correction: iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering
WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects the version issued on July 24, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not currently affiliated with …
Abivax Announces Closing of $747.5 Million Public Offering
Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing …
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD fully enrolled to support …
Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine
Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Mont-Saint-Guibert, Belgium – July 28, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology …